9.500 +0.12 (1.33%)
Pre-market: 8:15AM EST
|Bid||9.400 x 1000|
|Ask||10.500 x 2000|
|Day's range||9.300 - 9.750|
|52-week range||4.100 - 15.350|
|PE ratio (TTM)||N/A|
|Earnings date||7 Aug 2017 - 11 Aug 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||27.58|
US IND Filing Expected in the First Half of 2018
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, CA. The presentation is scheduled to take place on Thursday, January 11, 2018 at 7:30am PT. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases.
On a per-share basis, the New York-based company said it had a loss of 48 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...